Dionne Janis M
Division of Nephrology, Department of Pediatrics, University of British Columbia, BC Children's Hospital, 4480 Oak Street, Vancouver, BC, V6H 3V4, Canada.
Pediatr Nephrol. 2015 Nov;30(11):1919-27. doi: 10.1007/s00467-015-3077-7. Epub 2015 Mar 10.
Hypertension is common in children with chronic kidney disease and early evidence suggests that it is a modifiable risk factor for renal and cardiovascular outcomes. Recommendations for blood pressure management in children with chronic kidney disease can be found in various clinical practice guidelines including the 4th Task Force Report, the European Society of Hypertension pediatric recommendations, and the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the management of blood pressure in chronic kidney disease. Unfortunately, as pediatric trial evidence is limited, there are discrepancies in the recommendations that may lead to inconsistent clinical care and practice variation. This article reviews the strength of evidence behind each of the clinical practice guideline recommendations regarding blood pressure assessment, treatment targets, and first-line antihypertensive medications. The benefits and cautions of use of clinical practice guidelines are described with emphasis on the importance of reading beyond the summary statements.
高血压在慢性肾脏病儿童中很常见,早期证据表明它是影响肾脏和心血管预后的一个可改变的危险因素。有关慢性肾脏病儿童血压管理的建议可在各种临床实践指南中找到,包括第四届特别工作组报告、欧洲高血压学会儿科建议、美国国家肾脏基金会肾脏病预后质量倡议(K/DOQI)以及改善全球肾脏病预后组织(KDIGO)关于慢性肾脏病血压管理的指南。遗憾的是,由于儿科试验证据有限,这些建议存在差异,可能导致临床护理不一致和实践差异。本文回顾了各项临床实践指南中关于血压评估、治疗目标和一线抗高血压药物建议背后的证据强度。文中描述了使用临床实践指南的益处和注意事项,强调了阅读总结声明之外内容的重要性。